Adaptin Bio, Inc.
APTN
$6.27
$0.000.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.00% | 24.14% | 210.00% | 187.28% | 1,334.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.06% | 34.53% | 169.24% | 68.45% | 98.21% |
| Operating Income | 21.06% | -34.53% | -169.24% | -68.45% | -98.21% |
| Income Before Tax | 20.75% | -90.03% | -59.66% | -51.28% | -85.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.75% | -90.03% | -59.66% | -51.28% | -85.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.75% | -90.03% | -59.66% | -51.28% | -85.77% |
| EBIT | 21.06% | -34.53% | -169.24% | -68.45% | -98.21% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 24.29% | -27.25% | 38.81% | 41.84% | 28.58% |
| Normalized Basic EPS | 24.29% | 17.45% | 20.88% | 41.83% | 28.59% |
| EPS Diluted | 22.22% | -27.25% | 38.58% | 41.31% | 28.54% |
| Normalized Diluted EPS | 24.29% | 17.45% | 20.88% | 41.83% | 28.59% |
| Average Basic Shares Outstanding | 4.67% | 49.34% | 161.01% | 160.18% | 160.14% |
| Average Diluted Shares Outstanding | 4.67% | 49.34% | 161.01% | 160.18% | 160.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |